ID   IMPA2_HUMAN             Reviewed;         288 AA.
AC   O14732; B0YJ29; Q9UJT3;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   15-MAR-2017, entry version 152.
DE   RecName: Full=Inositol monophosphatase 2;
DE            Short=IMP 2;
DE            Short=IMPase 2;
DE            EC=3.1.3.25;
DE   AltName: Full=Inositol-1(or 4)-monophosphatase 2;
DE   AltName: Full=Myo-inositol monophosphatase A2;
GN   Name=IMPA2; Synonyms=IMP.18P;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9322233; DOI=10.1038/sj.mp.4000325;
RA   Yoshikawa T., Turner G., Esterling L.E., Sanders A.R.,
RA   Detera-Wadleigh S.D.;
RT   "A novel human myo-inositol monophosphatase gene, IMP.18p, maps to a
RT   susceptibility region for bipolar disorder.";
RL   Mol. Psychiatry 2:393-397(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10822345; DOI=10.1038/sj.mp.4000681;
RA   Sjoeholt G., Gulbrandsen A.K., Lovlie R., Berle J., Molven A.,
RA   Steen V.M.;
RT   "A human myo-inositol monophosphatase gene (IMPA2) localized in a
RT   putative susceptibility region for bipolar disorder on chromosome
RT   18p11.2: genomic structure and polymorphism screening in manic-
RT   depressive patients.";
RL   Mol. Psychiatry 5:172-180(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Parthasarathy L., Parthasarathy R.;
RT   "Molecular characterization of a novel form of human brain inositol
RT   monophosphatase A2b.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   ENZYME REGULATION.
RX   PubMed=15504365; DOI=10.1016/j.bbrc.2004.09.199;
RA   Seelan R.S., Parthasarathy L.K., Parthasarathy R.N.;
RT   "Lithium modulation of the human inositol monophosphatase 2 (IMPA2)
RT   promoter.";
RL   Biochem. Biophys. Res. Commun. 324:1370-1378(2004).
RN   [9]
RP   FUNCTION, MUTAGENESIS OF ASP-104, ENZYME REGULATION, COFACTOR,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND HOMODIMERIZATION.
RX   PubMed=17068342; DOI=10.1074/jbc.M604474200;
RA   Ohnishi T., Ohba H., Seo K.-C., Im J., Sato Y., Iwayama Y.,
RA   Furuichi T., Chung S.-K., Yoshikawa T.;
RT   "Spatial expression patterns and biochemical properties distinguish a
RT   second myo-inositol monophosphatase IMPA2 from IMPA1.";
RL   J. Biol. Chem. 282:637-646(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH SUBSTRATE, AND
RP   HOMODIMERIZATION.
RX   PubMed=17340635; DOI=10.1002/prot.21299;
RA   Arai R., Ito K., Ohnishi T., Ohba H., Akasaka R., Bessho Y.,
RA   Hanawa-Suetsugu K., Yoshikawa T., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of human myo-inositol monophosphatase 2, the
RT   product of the putative susceptibility gene for bipolar disorder,
RT   schizophrenia, and febrile seizures.";
RL   Proteins 67:732-742(2007).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 16-288.
RG   Structural genomics consortium (SGC);
RT   "Structure of human inositol monophosphatase 2.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Can use myo-inositol monophosphates, scylloinositol 1,4-
CC       diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'-
CC       AMP as substrates. Has been implicated as the pharmacological
CC       target for lithium Li(+) action in brain.
CC       {ECO:0000269|PubMed:17068342}.
CC   -!- CATALYTIC ACTIVITY: Myo-inositol phosphate + H(2)O = myo-inositol
CC       + phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17068342};
CC   -!- ENZYME REGULATION: Inhibited by high Li(+) and restricted Mg(2+)
CC       concentrations. {ECO:0000269|PubMed:15504365,
CC       ECO:0000269|PubMed:17068342}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5 mM for myo-inositol 1-monophosphate
CC         {ECO:0000269|PubMed:17068342};
CC       pH dependence:
CC         Optimum pH is 7.5-8.0. {ECO:0000269|PubMed:17068342};
CC   -!- PATHWAY: Polyol metabolism; myo-inositol biosynthesis; myo-
CC       inositol from D-glucose 6-phosphate: step 2/2.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:17340635}.
CC   -!- INTERACTION:
CC       P29218:IMPA1; NbExp=3; IntAct=EBI-725233, EBI-752410;
CC       Q8TBC4:UBA3; NbExp=5; IntAct=EBI-725233, EBI-717567;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14732-1; Sequence=Displayed;
CC       Name=2; Synonyms=A2b;
CC         IsoId=O14732-2; Sequence=VSP_013674;
CC   -!- INDUCTION: Repressed by Li(+).
CC   -!- SIMILARITY: Belongs to the inositol monophosphatase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF014398; AAB70915.1; -; mRNA.
DR   EMBL; AF157102; AAD40683.1; -; Genomic_DNA.
DR   EMBL; AF157096; AAD40683.1; JOINED; Genomic_DNA.
DR   EMBL; AF157097; AAD40683.1; JOINED; Genomic_DNA.
DR   EMBL; AF157098; AAD40683.1; JOINED; Genomic_DNA.
DR   EMBL; AF157099; AAD40683.1; JOINED; Genomic_DNA.
DR   EMBL; AF157100; AAD40683.1; JOINED; Genomic_DNA.
DR   EMBL; AF157101; AAD40683.1; JOINED; Genomic_DNA.
DR   EMBL; AF200432; AAF07824.1; -; mRNA.
DR   EMBL; BT007061; AAP35710.1; -; mRNA.
DR   EMBL; EF444990; ACA06007.1; -; Genomic_DNA.
DR   EMBL; CH471113; EAX01559.1; -; Genomic_DNA.
DR   EMBL; BC017176; AAH17176.1; -; mRNA.
DR   CCDS; CCDS11855.1; -. [O14732-1]
DR   RefSeq; NP_055029.1; NM_014214.2. [O14732-1]
DR   UniGene; Hs.743311; -.
DR   PDB; 2CZH; X-ray; 2.70 A; A/B=1-288.
DR   PDB; 2CZI; X-ray; 3.00 A; A=1-288.
DR   PDB; 2CZK; X-ray; 2.90 A; A=1-288.
DR   PDB; 2DDK; X-ray; 2.70 A; A/B=1-288.
DR   PDB; 2FVZ; X-ray; 2.40 A; A/B/C/D=16-288.
DR   PDBsum; 2CZH; -.
DR   PDBsum; 2CZI; -.
DR   PDBsum; 2CZK; -.
DR   PDBsum; 2DDK; -.
DR   PDBsum; 2FVZ; -.
DR   ProteinModelPortal; O14732; -.
DR   SMR; O14732; -.
DR   BioGrid; 109826; 35.
DR   IntAct; O14732; 7.
DR   MINT; MINT-1413243; -.
DR   STRING; 9606.ENSP00000269159; -.
DR   DrugBank; DB01356; Lithium.
DR   DEPOD; O14732; -.
DR   iPTMnet; O14732; -.
DR   PhosphoSitePlus; O14732; -.
DR   BioMuta; IMPA2; -.
DR   EPD; O14732; -.
DR   MaxQB; O14732; -.
DR   PaxDb; O14732; -.
DR   PeptideAtlas; O14732; -.
DR   PRIDE; O14732; -.
DR   TopDownProteomics; O14732-2; -. [O14732-2]
DR   DNASU; 3613; -.
DR   Ensembl; ENST00000269159; ENSP00000269159; ENSG00000141401. [O14732-1]
DR   GeneID; 3613; -.
DR   KEGG; hsa:3613; -.
DR   UCSC; uc002kqp.3; human. [O14732-1]
DR   CTD; 3613; -.
DR   DisGeNET; 3613; -.
DR   GeneCards; IMPA2; -.
DR   HGNC; HGNC:6051; IMPA2.
DR   HPA; HPA029561; -.
DR   MIM; 605922; gene.
DR   neXtProt; NX_O14732; -.
DR   OpenTargets; ENSG00000141401; -.
DR   PharmGKB; PA29861; -.
DR   eggNOG; KOG2951; Eukaryota.
DR   eggNOG; COG0483; LUCA.
DR   GeneTree; ENSGT00390000014699; -.
DR   HOGENOM; HOG000282238; -.
DR   HOVERGEN; HBG052123; -.
DR   InParanoid; O14732; -.
DR   KO; K01092; -.
DR   OMA; GDPWKEC; -.
DR   OrthoDB; EOG091G0D21; -.
DR   PhylomeDB; O14732; -.
DR   TreeFam; TF313194; -.
DR   BioCyc; MetaCyc:HS06822-MONOMER; -.
DR   Reactome; R-HSA-1855183; Synthesis of IP2, IP, and Ins in the cytosol.
DR   UniPathway; UPA00823; UER00788.
DR   ChiTaRS; IMPA2; human.
DR   EvolutionaryTrace; O14732; -.
DR   GeneWiki; IMPA2; -.
DR   GenomeRNAi; 3613; -.
DR   PRO; PR:O14732; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000141401; -.
DR   CleanEx; HS_IMPA2; -.
DR   ExpressionAtlas; O14732; baseline and differential.
DR   Genevisible; O14732; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0008934; F:inositol monophosphate 1-phosphatase activity; IDA:MGI.
DR   GO; GO:0052832; F:inositol monophosphate 3-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052833; F:inositol monophosphate 4-phosphatase activity; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:MGI.
DR   GO; GO:0006021; P:inositol biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006020; P:inositol metabolic process; IBA:GO_Central.
DR   GO; GO:0046855; P:inositol phosphate dephosphorylation; IDA:MGI.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; TAS:ProtInc.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd01639; IMPase; 1.
DR   InterPro; IPR033942; IMPase.
DR   InterPro; IPR020583; Inositol_monoP_metal-BS.
DR   InterPro; IPR020552; Inositol_monoPase_Li-sen.
DR   InterPro; IPR000760; Inositol_monophosphatase-like.
DR   InterPro; IPR020550; Inositol_monophosphatase_CS.
DR   PANTHER; PTHR20854; PTHR20854; 1.
DR   Pfam; PF00459; Inositol_P; 1.
DR   PRINTS; PR00377; IMPHPHTASES.
DR   PRINTS; PR00378; LIIMPHPHTASE.
DR   PROSITE; PS00629; IMP_1; 1.
DR   PROSITE; PS00630; IMP_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Hydrolase;
KW   Magnesium; Metal-binding; Polymorphism; Reference proteome.
FT   CHAIN         1    288       Inositol monophosphatase 2.
FT                                /FTId=PRO_0000142520.
FT   REGION      103    106       Substrate binding.
FT   REGION      205    207       Substrate binding.
FT   METAL        81     81       Magnesium 1. {ECO:0000250}.
FT   METAL       101    101       Magnesium 1. {ECO:0000250}.
FT   METAL       101    101       Magnesium 2. {ECO:0000250}.
FT   METAL       103    103       Magnesium 1; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       104    104       Magnesium 2. {ECO:0000250}.
FT   METAL       231    231       Magnesium 2. {ECO:0000250}.
FT   BINDING      81     81       Substrate. {ECO:0000269|PubMed:17340635}.
FT   BINDING     224    224       Substrate. {ECO:0000269|PubMed:17340635}.
FT   BINDING     231    231       Substrate. {ECO:0000250}.
FT   VAR_SEQ       6     34       EDQAALAAGPWEECFQAAVQLALRAGQII -> QD (in
FT                                isoform 2). {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_013674.
FT   VARIANT      88     88       A -> T (in dbSNP:rs16976948).
FT                                /FTId=VAR_049601.
FT   MUTAGEN     104    104       D->N: Loss of activity.
FT                                {ECO:0000269|PubMed:17068342}.
FT   HELIX        17     38       {ECO:0000244|PDB:2FVZ}.
FT   HELIX        56     70       {ECO:0000244|PDB:2FVZ}.
FT   STRAND       77     84       {ECO:0000244|PDB:2CZH}.
FT   STRAND       97    104       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       106    110       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      117    124       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      127    135       {ECO:0000244|PDB:2FVZ}.
FT   TURN        136    139       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      140    145       {ECO:0000244|PDB:2FVZ}.
FT   TURN        146    148       {ECO:0000244|PDB:2CZH}.
FT   STRAND      150    152       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       165    167       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      169    171       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       180    195       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      199    203       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       207    215       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      220    226       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       229    231       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       233    241       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      245    247       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      251    253       {ECO:0000244|PDB:2CZH}.
FT   HELIX       256    258       {ECO:0000244|PDB:2FVZ}.
FT   STRAND      260    266       {ECO:0000244|PDB:2FVZ}.
FT   HELIX       267    275       {ECO:0000244|PDB:2FVZ}.
SQ   SEQUENCE   288 AA;  31321 MW;  30D83FA339AC69B4 CRC64;
     MKPSGEDQAA LAAGPWEECF QAAVQLALRA GQIIRKALTE EKRVSTKTSA ADLVTETDHL
     VEDLIISELR ERFPSHRFIA EEAAASGAKC VLTHSPTWII DPIDGTCNFV HRFPTVAVSI
     GFAVRQELEF GVIYHCTEER LYTGRRGRGA FCNGQRLRVS GETDLSKALV LTEIGPKRDP
     ATLKLFLSNM ERLLHAKAHG VRVIGSSTLA LCHLASGAAD AYYQFGLHCW DLAAATVIIR
     EAGGIVIDTS GGPLDLMACR VVAASTREMA MLIAQALQTI NYGRDDEK
//
